Clovis Oncology (CLVS) : Wednesdays money flow data in Clovis Oncology (CLVS) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $30.62 million, whereas, $28.9 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.06, in favor of the bulls. The total money flow into the stock was $1.71 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $1.58 million. The total value of block trades done on upticks was $1.58 million. Clovis Oncology (CLVS) fell $0.83 and traded at $36.61, down -2.22% for the day, over previous days close. On a weekly basis, the shares are -1.43% over the previous weeks close.
Shares of Clovis Oncology, Inc. rose by 1.85% in the last five trading days and 55.37% for the last 4 weeks. Clovis Oncology, Inc. is up 141.3% in the last 3-month period. Year-to-Date the stock performance stands at 3.83%.
Clovis Oncology (CLVS) : Zacks Investment Research ranks Clovis Oncology (CLVS) as 2, which is a Buy recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 2.33, which indicates as a Buy.
Clovis Oncology (NASDAQ:CLVS): stock was range-bound between the intraday low of $35.63 and the intraday high of $37.94 after having opened at $37.61 on Wednesdays session. The stock finally closed in the red at $37.61, a loss of -2.94%. The stock remained in the red for the whole trading day. The total traded volume was 3,469,390 shares. The stock failed to cross $37.94 in Wednesdays trading. The stocks closing price on Thursday was $37.44.
Clovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.